市場調査レポート

臨床開発の新興市場:アジア

Emerging Markets Clinical Development Series: Asia

発行 Cutting Edge Information 商品コード 143473
出版日 ページ情報 英文 193 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
臨床開発の新興市場:アジア Emerging Markets Clinical Development Series: Asia
出版日: 2010年11月30日 ページ情報: 英文 193 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、アジアにおける臨床開発市場について分析し、中国、インドを中心とした各国別の臨床開発戦略と動向、プロファイルをまとめ、概略下記の構成でお届けいたします。

アジアにおける臨床開発:東西の最善策を活用

  • アジアのスコアリング
  • 調査方法
  • 参加企業
  • レポートレイアウト
  • プロファイルレイアウト
  • アジアにおける治験実施:成功のための提言

中国

  • 臨床環境概要
  • 臨床開発戦略
  • 臨床開発プロファイル

インド

  • 臨床環境概要
  • 臨床開発戦略
  • 臨床開発プロファイル
  • その他の中欧・東欧諸国における動向

その他のアジア諸国

  • 臨床開発プロファイル
目次
Product Code: PH144

Abstract

Asia offers clinical development teams unique benefits for running trials. Among emerging markets, Asian countries offer the highest number of available patients. The region also hosts a thriving pharmaceutical and biotechnology industry, and medical education among investigators has come in-line with Western expectations for Good Clinical Practice. Asia presents an interesting mix of Western knowledge and Eastern practice that has resulted in significant scientific and medical advances. As more companies move clinical trials into this region, they will benefit for years to come from the expertise inherent in Asian markets. This study is an ideal resource designed to address the challenges and answer your most burning questions about conducting clinical trials in Asia. It provides detailed data on China and India as well as profiles of companies that are conducting trials in Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines. Learn the advantages and challenges that each of these countries presents. Use the benchmarks, metrics and best practices to avoid common pitfalls and solidify your clinical strategy:

  • Intellectual property concerns: Asia has a reputation for poor intellectual property protections. But this report uncovers the progress made in China, India and other Asian nations around IP protection. The report will also help you navigate regulations, healthcare infrastructure, costs and patient access.
  • Physician-patient relationships: Learn about the strong physician-patient relationships created in Asian countries. Tap into these bonds to boost enrollment and retention for your clinical studies.
  • Individual country benefits: Too often, companies approach specific emerging markets with regional strategies. This report illustrates the benefits that each individual country provides so that you can develop detailed plans for running trials in each market. Tap into the best ratios of cost, quality and timelines while using local partners to navigate culture, communication and regulations.

Table of Contents

  • 9 Clinical Development in Asia: Harnessing the Best of the East and West
  • 11 Scoring Asia
  • 30 Study Methodology
  • 31 Participating Companies
  • 32 Report Layout
  • 33 Profile Layout
  • 36 Running Trials in Asia: Key Recommendations for Success
  • 43 China
  • 44 Clinical Environment Overview
  • 58 Clinical Development Strategy
  • 74 Clinical Development Profiles
  • 95 India
  • 96 Clinical Environment Overview
  • 109 Clinical Development Strategy
  • 130 Clinical Development Profiles
  • 159 Other Emerging Asian Countries
  • 162 Clinical Development Profiles

CHARTS AND GRAPHICS

Executive Summary

Scoring Asia

  • 12 Figure E.1: Asian Population Compared to US and 5 EU Countries
  • 13 Figure E.2: Number of Studies Registered by Region
  • 13 Figure E.3: Number of Studies Registered in Profiled Asian Countries
  • 15 Figure E.4: Scoring Asia: Patient Access
  • 15 Figure E.5: Scoring Asia: Patient Retention
  • 17 Figure E.6: Scoring Asia: Regulatory Environment
  • 18 Figure E.7: Scoring Asia: Intellectual Property Laws/Practice
  • 20 Figure E.8: Scoring Asia: Cultural Concerns
  • 20 Figure E.9: Scoring Asia: Communication/Language
  • 22 Figure E.10: Scoring Asia: Trial Technology Infrastructure
  • 22 Figure E.11: Scoring Asia: Supply Chain Management
  • 24 Figure E.12: Scoring Asia: Available Knowledge Base
  • 25 Figure E.13: Scoring Asia: Data Standards
  • 25 Figure E.14: Scoring Asia: Investigator Standards
  • 26 Figure E.15: Scoring Asia: Site Management Standards
  • 27 Figure E.16: Average Percentage of Budget Saved by Running a Site in Asia
  • 28 Figure E.17: Average Percentage of Time Saved by Running a Site in Asia
  • 29 Figure E.18: Scoring Asia: Anticipated Cost

China

Clinical Development Strategy

  • 44 Table 1.1: Key Demographic Figures for China (2010)
  • 45 Figure 1.1: Change in Life Expectancy: China (1960 - 2050)
  • 46 Table 1.2: Top 10 Causes of Death in China (2002)
  • 47 Figure 1.2: Ethnicities in China (2000 Census)
  • 50 Table 1.3: China' s Key Economic Figures (2009)
  • 52 Table 1.4: China' s Key Healthcare System Figures, 2005-2009
  • 53 Figure 1.3: China Healthcare Spending as a Percentage of GDP (2009)
  • 54 Figure 1.4: China' s Health Spending by Sector (2005)

Clinical Environment Overview

  • 60 Figure 1.5: Percentage of Budget Saved by Running a Trial in China
  • 60 Figure 1.6: Percentage of Time Saved by Running a Trial in China
  • 61 Figure 1.7: Assigning Clinical Development Responsibilities for China
  • 63 Figure 1.8: Scoring China: Clinical Environment Scores

64 Figure 1.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in China

  • 69 Figure 1.10: Importance of Factors that Impact Trial Operations for Companies Operating in China
  • 70 Figure 1.11: Scoring China: Trial Operations Scores
  • 73 Figure 1.12: Percent of Total Trial Patients Enrolled in China

Clinical Development Profiles

  • 74 Figure 1.13: Profile 1: Company Background
  • 75 Figure 1.14: Profile 1: Experience in Asia
  • 76 Figure 1.15: Profile 1: Clinical Strategy in China
  • 77 Figure 1.16: Profile 1: Scorecard for China
  • 78 Figure 1.17: Profile 2: Company Background
  • 79 Figure 1.18: Profile 2: Experience in Asia
  • 80 Figure 1.19: Profile 2: Clinical Strategy in China
  • 81 Figure 1.20: Profile 2: Scorecard for China
  • 82 Figure 1.21: Profile 3: Company Background
  • 83 Figure 1.22: Profile 3: Experience in Asia
  • 84 Figure 1.23: Profile 3: Clinical Strategy in China
  • 85 Figure 1.24: Profile 3: Scorecard for China
  • 86 Figure 1.25: Profile 4: Company Background
  • 87 Figure 1.26: Profile 4: Experience in Asia
  • 88 Figure 1.27: Profile 4: Clinical Strategy in China
  • 89 Figure 1.28: Profile 4: Scorecard for China
  • 90 Figure 1.29: Profile 5: Company Background
  • 91 Figure 1.30: Profile 5: Experience in Asia
  • 92 Figure 1.31: Profile 5: Clinical Strategy in China
  • 93 Figure 1.32: Profile 5: Scorecard for China

India

Clinical Environment Overview

  • 97 Table 2.1: Key Demographic Figures for India (2010)
  • 98 Figure 2.1: Change in Life Expectancy (1960-2050)
  • 99 Table 2.2: Top Ten Causes of Death in India (2002)
  • 101 Figure 2.2: Ethnicities in India (2000 Census)
  • 103 Table 2.3: Key Economic Figures (2009)
  • 104 Figure 2.3: India' s Healthcare Spending as a Percent of GDP (2006)
  • 105 Figure 2.4: Health Spending by Sector (2005)
  • 106 Table 2.4: Key Healthcare System Figures (2005 - 2009)

Clinical Development Strategy

  • 110 Figure 2.5: Assigning Clinical Development Responsibilities for India
  • 115 Figure 2.6: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in India
  • 116 Figure 2.7: Scoring India: Clinical Environment Scores
  • 123 Figure 2.8: Importance of Factors that Impact Trial Operations for Companies Operating in India
  • 123 Figure 2.9: Scoring India: Trial Operations Scores
  • 125 Figure 2.10: Percent of Total Trial Patients Enrolled in India
  • 128 Figure 2.11: Percentage of Budget Saved by Running a Trial in India
  • 128 Figure 2.12: Percentage of Time Saved by Running a Trial in India

Clinical Development Profiles

  • 130 Figure 2.13: Profile 6: Company Background
  • 131 Figure 2.14: Profile 6: Experience in Asia
  • 132 Figure 2.15: Profile 6: Clinical Strategy in India
  • 133 Figure 2.16: Profile 6: Scorecard for India
  • 134 Figure 2.17: Profile 7: Company Background
  • 135 Figure 2.18: Profile 7: Experience in Asia
  • 136 Figure 2.19: Profile 7: Clinical Strategy in India
  • 137 Figure 2.20: Profile 7: Scorecard for India
  • 138 Figure 2.21: Profile 8: Company Background
  • 139 Figure 2.22: Profile 8: Experience in Asia
  • 140 Figure 2.23: Profile 8: Clinical Strategy in India
  • 141 Figure 2.24: Profile 8: Scorecard for India
  • 142 Figure 2.25: Profile 9: Company Background
  • 143 Figure 2.26: Profile 9: Experience in Asia
  • 144 Figure 2.27: Profile 9: Clinical Strategy in India
  • 145 Figure 2.28: Profile 9: Scorecard for India
  • 146 Figure 2.29: Profile 10: Company Background
  • 147 Figure 2.30: Profile 10: Experience in Asia
  • 148 Figure 2.31: Profile 10: Clinical Strategy in India
  • 149 Figure 2.32: Profile 10: Scorecard for India
  • 150 Figure 2.33: Profile 11: Company Background
  • 151 Figure 2.34: Profile 11: Experience in Asia
  • 152 Figure 2.35: Profile 11: Clinical Strategy in India
  • 153 Figure 2.36: Profile 11: Scorecard for India
  • 154 Figure 2.37: Profile 12: Company Background
  • 155 Figure 2.38: Profile 12: Experience in Asia
  • 156 Figure 2.39: Profile 12: Clinical Strategy in India
  • 157 Figure 2.40: Profile 12: Scorecard for India

Other Emerging Asian Countries

Clinical Development Profiles

  • 162 Figure 3.1: Profile 13: Company Background
  • 163 Figure 3.2: Profile 13: Experience in Asia
  • 164 Figure 3.3: Profile 13: Clinical Strategy in Hong Kong
  • 165 Figure 3.4: Profile 13: Scorecard for Hong Kong
  • 166 Figure 3.5: Profile 14: Company Background
  • 167 Figure 3.6: Profile 14: Experience in Asia
  • 168 Figure 3.7: Profile 14: Clinical Strategy in Malaysia
  • 169 Figure 3.8: Profile 14: Scorecard for Malaysia
  • 170 Figure 3.9: Profile 15: Company Background
  • 171 Figure 3.10: Profile 15: Experience in Asia
  • 172 Figure 3.11: Profile 15: Clinical Strategy in Philippines
  • 173 Figure 3.12: Profile 15: Scorecard for Philippines
  • 174 Figure 3.13: Profile 16: Company Background
  • 175 Figure 3.14: Profile 16: Experience in Asia
  • 176 Figure 3.15: Profile 16: Clinical Strategy in Singapore
  • 177 Figure 3.16: Profile 16: Scorecard for Singapore
  • 178 Figure 3.17: Profile 17: Company Background
  • 179 Figure 3.18: Profile 17: Experience in Asia
  • 180 Figure 3.19: Profile 17: Clinical Strategy in South Korea
  • 181 Figure 3.20: Profile 17: Scorecard for South Korea
  • 182 Figure 3.21: Profile 18: Company Background
  • 183 Figure 3.22: Profile 18: Experience in Asia
  • 184 Figure 3.23: Profile 18: Clinical Strategy in Taiwan
  • 185 Figure 3.24: Profile 18: Scorecard for Taiwan
  • 186 Figure 3.25: Profile 19: Company Background
  • 187 Figure 3.26: Profile 19: Experience in Asia
  • 188 Figure 3.27: Profile 19: Clinical Strategy in Thailand
  • 189 Figure 3.28: Profile 19: Scorecard for Thailand
  • 190 Figure 3.29: Profile 20: Company Background
  • 191 Figure 3.30: Profile 20: Experience in Asia
  • 192 Figure 3.31: Profile 20: Clinical Strategy in Thailand
  • 193 Figure 3.32: Profile 20: Scorecard for Thailand
Back to Top